论文部分内容阅读
目的探讨前列腺癌患者血清和病理组织中miRNA-375的表达及临床意义。方法选取2015年3月至2016年3月间我院收治的前列腺癌患者30例为观察组,另选择同期前列腺增生患者30例为对照组,检测并比较两组患者血清及病理组织中miRNA-375变化,观察血清miRNA-375表达与临床病理关系,分析病理组织与血清中mi-RNA-375相关性及前列腺癌患者血清miRNA-375与血清PSA的相关性。结果与前列腺增生患者比较,前列腺癌患者PCR定量检测miRNA-375血清中2-△Ct显著增高,病理组织中miRNA-375表达显著升高,差异有统计学意义(P<0.05)。病理分期T3~T4期、Gleason评分>7分、存在转移及PSA>10μg/L者显著高于病理分期T1~T2期、Gleason评分≤7分、无转移及PSA≤10μg/L者,差异有统计学意义(P<0.05)。前列腺癌患者mi-RNA-375与血清PSA呈线性相关(r=0.714,P<0.05)。前列腺癌病理组织与血清中mi-RNA-375呈线性相关(r=0.911,P<0.05)。结论前列腺癌患者血清miRNA-375水平存在明显升高,且与患者临床病理特征存在相关性。
Objective To investigate the expression and clinical significance of miRNA-375 in serum and pathological tissues of patients with prostate cancer. Methods Thirty patients with prostate cancer who were treated in our hospital from March 2015 to March 2016 were selected as observation group and 30 patients with benign prostatic hyperplasia were selected as control group in the same period. The levels of miRNA- 375, the relationship between serum miRNA-375 expression and clinical pathology was analyzed. The correlation between pathological tissue and serum miRNA-375 and serum miRNA-375 in patients with prostate cancer and serum PSA were analyzed. Results Compared with benign prostatic hyperplasia patients, the quantity of 2- △ Ct in miRNA-375 serum of patients with prostate cancer was significantly increased, while the expression of miRNA-375 in pathological tissues was significantly increased (P <0.05). Pathological stage T3 ~ T4, Gleason score> 7 points, metastasis and PSA> 10μg / L were significantly higher than the pathological stage T1 ~ T2, Gleason score ≤ 7 points, no metastasis and PSA ≤ 10μg / L, the difference was Statistical significance (P <0.05). Prostate cancer patients mi-RNA-375 and serum PSA was linear (r = 0.714, P <0.05). Prostate cancer pathological tissue and serum mi-RNA-375 was linear (r = 0.911, P <0.05). Conclusion The serum level of miRNA-375 in patients with prostate cancer is significantly increased, which is correlated with the clinicopathological features.